Search results for " bclc"

showing 3 items of 3 documents

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

2020

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional surviva…

macro-vascular portal vein invasionMaleCarcinoma HepatocellularAntineoplastic Agentsextra hepatic disease and BCLCsurvivalNLRAntineoplastic AgentCohort Studiesalpha-fetoproteinHumansLymphocyte CountSurvivorsprognostic factorAgedLiver NeoplasmsMiddle AgedSorafenibProgression-Free SurvivalItalyLiver Neoplasmalpha-fetoprotein; extra hepatic disease and BCLC; hepatitis C; macro-vascular portal vein invasion; NLR; prognostic factor; survivalFemaleCohort Studiehepatitis CCarcinoma Hepatocellular ...Liver Neoplasms ...Human
researchProduct

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

2017

Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follo…

SorafenibMaleNiacinamidemedicine.medical_specialtyStandard of careCarcinoma HepatocellularAntineoplastic AgentsGastroenterologyIntermediate stage03 medical and health sciences0302 clinical medicineHCC; BCLC-B; Intermediate stage; Treatment; HepatologyInternal medicinemedicineHumansChemoembolization TherapeuticHCCPropensity ScoreAgedNeoplasm StagingRetrospective Studiesintermediate stageHepatologytreatmentbusiness.industryPatient SelectionPhenylurea CompoundsLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAStandard of CareHepatologyMiddle AgedSorafenibmedicine.diseaseSurvival AnalysisTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matchingMultivariate Analysis030211 gastroenterology & hepatologyFemaleLiver functionLiver cancerbusinessBCLC-Bmedicine.drug
researchProduct

Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

2022

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients…

NiacinamideCarcinoma HepatocellularHepatocellular carcinomahepatocellular carcinoma surgery sorafenib bclcPhenylurea CompoundsCarcinomaSettore MED/09 - MEDICINA INTERNALiver Neoplasmsadvanced HCCHepatocellularAntineoplastic Agentssystemic therapies.SorafenibBCLC CNOTreatment Outcomesystemic therapiesmacrovascular invasionHumansHepatectomySurgeryHepatectomy; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Antineoplastic Agents; Carcinoma Hepatocellular; Liver NeoplasmsLiver surgeryNeoplasm StagingRetrospective Studies
researchProduct